[On a new hypertensive agent with predominant central action, 2-(2,6-dichlorophenylamino)-2-imidazolinhydrochloride (St 155)].
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001810:Blood Volume / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced; D002490:Central Nervous System / Q000187:drug effects*; D003864:Depression, Chemical; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology
D000959:Antihypertensive Agents; D007093:Imidazoles
Uber ein neues Antihypertensivum mit vorwiegend zentralen Angriffspunkt, 2-(2,6-Dichlorphenylamino-2-imidazolinhydrochlorid (St 155)